|Bid||4.2000 x 27000|
|Ask||4.2200 x 3200|
|Day's Range||3.8300 - 4.2300|
|52 Week Range||1.1200 - 6.4700|
|Beta (5Y Monthly)||1.85|
|PE Ratio (TTM)||87.92|
|Earnings Date||May 04, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.25|
Chairman Frost Phillip Md Et Al filed a Form 4 with the SEC on Monday, February 22. The insider bought 28,802 shares of OPKO Health Inc (NASDAQ:OPK) at an average price of $4.81. After the transaction, the executive's stake in OPKO Health Inc. moved to 191,871,694 shares. OPKO Health was trading 1.3% lower from the previous closing price. Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision. When an insider buys stock after an important sell off, that can indicate the insider's faith in the success of the organization. Henceforth, if the stock is bought at new highs, it might be because the insider feels that the stock is not overvalued. Conversely, insiders who are selling stock at new lows can potentially indicate some kind of capitulation moment. Insiders selling at new highs can indicate that exec wants to "take some profit" and "lock in a gain." Important Transaction Codes Wall Street tends to focus on insider transactions which take place in the open market, viewed inside a Form 4 filing via codes P for purchase and S for sale. An open-market transaction means the insider went into the market of their own volition and made an active decision about the potential path for a company and its stock moving forward. Transaction codes besides P or S aren't relatively important as they are seldom tied to a decision by the executive. For example, transaction code A is indicative of an insider being forced to sell shares to attain compensation. Moreover, transaction code C indicates the conversion of an option. See more from BenzingaClick here for options trades from BenzingaROCE Insights For OPKO HealthOPKO Health: Q4 Earnings Insights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Looking at Q4, OPKO Health (NASDAQ:OPK) earned $49.36 million, a 124.97% increase from the preceding quarter. OPKO Health also posted a total of $494.60 million in sales, a 15.53% increase since Q3. OPKO Health earned $21.94 million, and sales totaled $428.10 million in Q3. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, OPKO Health posted an ROCE of 0.03%. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. View more earnings on OPK Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders. For OPKO Health, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies. Q4 Earnings Insight OPKO Health reported Q4 earnings per share at $0.05/share, which beat analyst predictions of $0.04/share. See more from BenzingaClick here for options trades from BenzingaOPKO Health: Q4 Earnings InsightsEarnings Scheduled For February 18, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View more earnings on OPKSee more from BenzingaClick here for options trades from BenzingaClearPoint Neuro Secures M Via Equity At 9% DiscountProvention Bio Announces China Deal For Autoimmune Program© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.